AngioDynamics, Inc.

AngioDynamics, Inc.

AngioDynamics, Inc.

Overview
Date Founded

1992

Headquarters

14 Plaza Drive, Latham, NY, 12110, USA

Type of Company

Public

Employees (Worldwide)

1,145

Industries

Medical Products & Equipment
Computer Software
Appliances & Electronics
Hospitals & Patient Services

Company Description

AngioDynamics, Inc. engages in the development, manufacture, and sale of medical devices for vascular access, surgery, peripheral vascular disease, and oncology. It offers ablation systems, fluid management systems, vascular access, angiographic, drainage. thrombolytic, and venous products. The company was founded by Eamonn P. Hobbs in 1988 and is headquartered in Latham, NY.

Contact Data
Trying to get in touch with decision makers at AngioDynamics, Inc.? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

President & Chief Executive Officer

Executive Vice President, Chief Accounting Officer & Chief Financial Officer

Chief Financial Officer, Vice President & Controller

Senior Vice President & General Counsel

Senior Vice President & General Manager, Vascular Access

Senior Vice President & General Manager, Vascular Access

Senior Vice President & General Manager for Vascular Interventions & Therapies

Senior Vice President & General Manager of Oncology

Senior Vice President of Global Operations & R&D

Senior Vice President, Human Resources

Board of Directors

President & Chief Executive Officer at Bluefin Medical, Inc.

President & Chief Executive Officer at AngioDynamics, Inc.

Executive Chairman at Optum

Professional at AngioDynamics, Inc.

Professional at Stepan Co.

Venture Partner, MedTech at ONSET Ventures

Director at Blue Water Growth

Paths to AngioDynamics, Inc.
Potential Connections via
Relationship Science
You
AngioDynamics, Inc.
Owners & Shareholders
Details Hidden

Heartland Advisors uses a value investment philosophy to select equity securities. They search for under-researched, under-followed and under-valued securities. As value investors, the firm seeks to capitalize on inefficiencies in the financial markets by investing in stocks whose current market prices are at significant discounts to their evaluation of their true or intrinsic value. In assessing the intrinsic value of a company, Heartland examines its cash flows and uses other traditional valuation measures such as price to book value, p/e ratio, p/c flow ratio and earnings growth. They typically sell securities when they consider them to be overvalued relative to other investments.

Details Hidden

Tributary Capital Management constructs portfolios based on their clients' investment objectives and specified restrictions or guidelines. They are active portfolio managers grounded in strong fundamental research and adherence to risk management. Investments in client accounts may include investments in common stocks, investment companies, ETFs, corporate and municipal bonds and US Government and agency bonds.Tributary's equity investment strategies include small, small/mid, large and all cap strategies. The firm uses a rigorous, bottom-up process that identifies high quality companies that are temporarily priced below their long-term intrinsic value. Tributary's balanced strategies invest the equity portion in the all cap value strategy, while the fixed income portion seeks to provide a relatively high level of income from fixed income investments.Tributary also serves as the registered investment advisor for the Tributary Funds, a registered open-end investment company which offers six investment portfolios: Tributary Small Company Fund; Tributary Growth Opportunities Fund; Tributary Balanced Fund; Tributary Short-Intermediate Bond Fund; Tributary Income Fund; and Tributary Nebraska Tax-Free Fund.Tributary has retained First National Fund Advisers, an affiliate registered with the SEC as a separately identifiable department of First National Bank of Omaha, to serve as the sub-advisor to the Tributary Growth Opportunities, Balanced, Short-Intermediate Bond, Income and Nebraska Tax-Free Funds.

Details Hidden

Granahan Investment Management (GIM) is an active domestic small-cap equity manager that offers the following investment products: Small-Cap Explorer, Small-Cap Core Growth, Small-Cap Discoveries, International Small-Cap, Focused Growth, Small-Cap Focused Growth. International ADR All-Cap SRI, and Granahan Funds plc,.GIM's Small Cap Explorer product invests in stocks of companies with market-cap of $500 million-$10 billion at the time of purchase. The portfolio generally carries 155-175 stocks. This product focuses on companies exhibiting the potential for increased earnings growth.The firm's Small Cap Core Growth product focuses on stocks with market-caps of $200 million-$1.5 billion at the time of purchase. The portfolio generally holds 140-160 stocks, and focuses on companies with strong and/or accelerating earnings growth.GIM's Small Cap Discoveries is a micro-cap product that focuses on companies with market-cap up to $700 million that exhibit a critical combination of superior growth prospects and attractive risk reward profile. The portfolio generally holds 70- 90 stocks.The Focused Growth portfolio consists of 30-40 stocks with market-cap up to $2 billion at purchase, generally in the consumer and technology sectors, which have the potential for strong earnings growth and offer favorable return potential according to a proprietary risk/reward calculation. This product is offered to non-US clients through Ireland-based Granahan Funds plc.The firm's Small Cap Advantage product is a distinct combination of two individual strategies: Small Cap Discoveries and Small Cap Focused Growth. The product focuses on companies with market-cap of $50 million-$2 billion. The portfolio typically holds 90-100 stocks.The International Small Cap invests primarily in small-cap stocks of companies in EAFE-based countries, with up to 10% exposure to emerging markets. GIM screens the universe of investable countries for stocks with $100 million-$5 billion in market-cap. This strategy employs a combination of bottom-up, fundamental company research with a forward-looking expected-return tool for portfolio construction. The portfolio typically holds +/- 65 stocks.GIM's International ADR All-Cap SRI product seeks to invest in growth-oriented non-US companies with strong fundamentals, reasonable valuations, and catalysts for change in order to achieve long-term capital appreciation. GIM employs inclusionary and exclusionary screening criteria to construct a portfolio that incorporates sustainable, responsible investing. The portfolio typically holds +/- 55 stocks.All products are offered on a separate account and sub-advised basis, except for the GIM's Small Cap Discoveries, which is also available to accredited investors through the private fund, GIM Small Cap Discoveries LLC.

Recent Transactions
Details Hidden

Medline Industries, Inc. purchases Angiodynamics, Inc. /NAMIC Fluid Management from AngioDynamics, Inc.

Details Hidden

AngioDynamics, Inc. purchases Radiadyne LLC

Details Hidden

AngioDynamics, Inc. issued Common Stock

Transaction Advisors
Legal Advisor

Advised onAngioDynamics, Inc. issued Common Stock

Auditor

Advised onAngioDynamics, Inc. issued Common Stock

Public Relations

Advised onAngioDynamics, Inc. purchases Microsulis Medical Ltd.

Co-Chair, Corporate Group

Advised onMedline Industries, Inc. purchases Angiodynamics, Inc. /NAMIC Fluid Management from AngioDynamics, Inc.

Legal Advisor

Advised onMedline Industries, Inc. purchases Angiodynamics, Inc. /NAMIC Fluid Management from AngioDynamics, Inc.

Public Relations

Advised onAngioDynamics, Inc. purchases Vortex Medical, Inc.

Advisors & Consultants
Legal Advisor

Partner at Sidley Austin LLP

Key Stats and Financials As of 2018
Market Capitalization
$744M
Total Enterprise Value
$806M
Earnings Per Share
$0.44
Revenue
$344M
Total Debt
$91.6M
Net Profit
$16.3M
EBITDAMargin
13.79%
EBITDA
$47.5M
Enterprise Value Sales
2.34x
Debt TEV
0.11x
Total Equity
$543M
TEVNet Income
49.32x
Three Year Compounded Annual Growth Rate Of Revenue
-0.81%
Five Year Compounded Annual Growth Rate Of Revenue
0.13%
Enterprise Value EBITDAOperating
16.97x
Non-Profit Donations & Grants
$1,000 - $2,499
2010
Investors
Details Hidden

Co-Founder at Avista Capital Partners

Suppliers
Merz Holding GmbH & Co. KG Holding Companies | Frankfurt, HE

Merz Holding GmbH & Co. KG operates as holding company with interest in providing economic and financial services. The company was founded in 1926 and is located in Frankfurt, Germany

InspireMD, Inc. Medical Products & Equipment | Boston, MA

InspireMD, Inc. is a medical device company, which engages in the development and commercialization of the stent platform technology for the treatment of complex vascular and coronary disease. Its products are marketed for use mainly in patients with acute coronary syndromes, notably acute myocardial infarction and saphenous vein graft coronary interventions. The company was founded in 2005 and is headquartered in Tel Aviv, Israel.

Competitors
Johnson & Johnson Pharmaceuticals - New Brunswick, New Jersey

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women's health, and wound care markets. The Pharmaceutical segment focuses on therapeutic areas such as immunology, infectious diseases ad vaccines, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The Medical Devices segment offers products used in the orthopedic, surgery, cardiovascular, diabetes care, and eye health fields. The company was founded by Robert Wood Johnson I, James Wood Johnson and Edward Mead Johnson Sr. in 1886 and is headquartered in New Brunswick, NJ.

Medtronic Plc Medical Products & Equipment - Dublin, DU

Medtronic Plc is a medical technology company, which develop, manufacture, distribute, and sell device-based medical therapies and services. It also provides services to the hospitals, physicians, clinicians, and patients. It operates through the following segments: Cardiac and Vascular Group; Minimally Invasive Technologies Group; Restorative Therapies Group; and Diabetes Group. The Cardiac and Vascular Group segment consist of three divisions: Cardiac Rhythm & Heart Failure, Coronary & Structural Heart, and Aortic & Peripheral Vascular. The Minimally Invasive Technologies Group segment comprises of three divisions: Surgical Innovations and Respiratory, Gastrointestinal, and Renal. The Restorative Therapies Group contains four divisions: Spine, Brain, Specialty Therapies, and Pain Therapies. The Diabetes Group segment focuses in the development, manufacturing, and marketing of products and services for the management of Type I and Type II diabetes. The company was founded in 1949 and is headquartered in Dublin, Ireland.

Becton, Dickinson & Co. Medical Products & Equipment - Franklin Lakes, New Jersey

BD is a medical technology company that serves healthcare institutions, life science researchers, clinical laboratories, industry and the general public. BD manufactures and sells a broad range of medical supplies, devices, laboratory equipment and diagnostic products. BD is headquartered in the United States and has offices in more than 50 countries worldwide.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by AngioDynamics, Inc.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of AngioDynamics, Inc.'s profile does not indicate a business or promotional relationship of any kind between RelSci and AngioDynamics, Inc..
  • be_ixf; php_sdk; php_sdk_1.4.15
  • https://relationshipscience.com/organization/angiodynamics-inc-291837
  • https://relationshipscience.com/organization/angiodynamics-inc-291837